TREM2 agonism enhances microglial phagocytosis of α-synuclein aggregates via DAP12 signaling. Alector AL002 anti-TREM2 antibody in Phase II represents clinical validation, but temporal dynamics, species divergence, and biomarker gaps remain critical challenges for translation.
No linked papers recorded for this hypothesis yet.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.